RxDoctor Payments Data

Susanne Thompson, DO

Internal Medicine · Tulsa, OKNPI 1033111547

Payments from drug & device makers

$1,887in general payments, 2019–2025

Across 34 payments — averaging $55.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$728
  • Novo Nordisk$687
  • AbbVie$153
  • Boehringer Ingelheim$142
  • Ascensia Diabetes Care US Inc.$100
  • GSK$34
  • plus $44 from 2 others

What the payments were for

  • Food & beverage$1,78895%
  • Education$1005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,887 in reported general payments places this provider in the 75th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$33,493
Medicare patients
67
Services billed
263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$112,767
MounjaroTirzepatide73$86,009
JardianceEmpagliflozin55$66,021
JanuviaSitagliptin Phosphate35$38,754
EliquisApixaban34$25,703
TrulicityDulaglutide15$20,676
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$11,350
JanumetSitagliptin Phos/Metformin Hcl13$9,162
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,518
Incruse ElliptaUmeclidinium Bromide12$3,976
Albuterol Sulfate HfaAlbuterol Sulfate77$2,145
Amlodipine Besylate337$2,120
Gabapentin134$2,022
Atorvastatin Calcium286$1,946
Omeprazole86$1,760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$687$112,76786 claims
Lilly USA, LLCMounjaro, Trulicity$728$106,68488 claims
Boehringer IngelheimJardiance$142$66,02155 claims
GSKTrelegy Ellipta, Incruse Ellipta$34$11,49424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →